Valuation: EMV Capital plc

Market Cap 14.96M 20.41M 17.48M 16.31M 28.12M 1.95B 28.67M 193M 75.41M 979M 76.64M 74.98M 3.24B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 13.93M 19.01M 16.28M 15.19M 26.18M 1.82B 26.7M 180M 70.22M 912M 71.37M 69.82M 3.02B EV / Sales 2026 *
4.06x
EV / Sales 2027 * 4.05x
Free-Float
52.46%
Yield 2026 *
-
Yield 2027 * -
1 month+0.94%
3 months+15.05%
6 months-5.31%
Current year-6.14%
1 week 52
Extreme 52
55
1 month 52
Extreme 52
55
Current year 44
Extreme 44
62
1 year 40
Extreme 40
62
3 years 34
Extreme 34
80.5
5 years 34
Extreme 34
137
10 years 9.75
Extreme 9.75
846
Manager TitleAgeSince
Chief Executive Officer 50 01/05/2020
Director of Finance/CFO 45 01/12/2025
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 50 14/10/2019
Director/Board Member 47 09/12/2022
Chairman 61 01/02/2023
Date Insider Type Main position Quantity % Market Cap.
1/8/26 A Buy 7,000 0.0250%
1/8/26 A Sell 7,000 0.0250%
12/19/25 A Buy

Director

34,484 0.1242%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+16.30%-11.57% 20.36M
-0.72%+2.61%+72.19%+36.22% 3.82B
+0.62%+0.21%-11.32%+2.45% 3.12B
-2.60%-1.81%+41.73%+33.94% 2.06B
-2.65%-0.80%+87.95%+209.25% 1.5B
0.00%0.00%-1.72%-7.02% 733M
+1.88%-2.96%+157.45%+217.14% 590M
0.00%0.00%-3.33%-7.05% 412M
0.00%0.00%-40.68%-75.18% 392M
0.00%0.00%+0.54%-13.02% 372M
Average -0.27%-0.28%+31.91%+38.51% 1.3B
Weighted average by Cap. -0.68%+1.16%+40.95%+47.23%

Financials

2026 *2027 *
Net sales 3.43M 4.68M 4.01M 3.74M 6.44M 448M 6.57M 44.34M 17.28M 224M 17.57M 17.18M 743M 3.75M 5.12M 4.38M 4.09M 7.05M 490M 7.19M 48.51M 18.91M 245M 19.22M 18.8M 813M
Net income - -
Net Debt -1.03M -1.4M -1.2M -1.12M -1.93M -134M -1.97M -13.3M -5.19M -67.31M -5.27M -5.16M -223M 233K 318K 272K 254K 437K 30.39M 446K 3.01M 1.17M 15.23M 1.19M 1.17M 50.42M
Logo EMV Capital plc
EMV Capital plc is a United Kingdom-based deep tech and life sciences venture capital (VC) investment group with an international portfolio of companies. The Company identifies, invests in, and builds high-growth companies in the United Kingdom and internationally. It focuses on generating returns for investors from the sectors and technologies. The Company has a portfolio of approximately 70 companies with a focus on life sciences, industrials, robotics & artificial intelligence (AI), and sustainability. Its portfolio includes AMR Bio, Wanda Health, Deeptech Recycling Technologies, EpiBone, Sofant Technologies, Q-Bot, and others. Its portfolio, Glycotest, is a liver disease diagnostics company commercializing novel and unique blood tests for life-threatening liver cancers and fibrosis-cirrhosis. ProAxsis Limited is a commercial biomarker-led research company supporting drug development and clinical research through specialist biomarker insights.
Employees
21
Date Price Change Volume
20/08/26 GBX 53.50 0.00% 12,675
19/08/26 GBX 53.50 0.00% 10,730
18/08/26 GBX 53.50 0.00% 2,225
17/08/26 GBX 53.50 0.00% 1,604
14/08/26 GBX 53.50 0.00% 23,020
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5350GBP
Average target price
1.320GBP
Spread / Average Target
+146.73%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EMVC Stock